SCHEMBL8907220

SCHEMBL8907220

CCc1c(C)sc(N)c1C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
FHIT P49789 1/20 0.53
CYP1A2 P05177 1/20 0.51
ALDH1A1 P00352 9/20 0.50
MAPT P10636 6/20 0.50
CNR2 P34972 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
GAA P10253 4/20 0.49
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CNR1 P21554 1/20 0.48
TSHR P16473 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
CASP1 P29466 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HCRTR1 O43613 1/20 0.46
LMNA P02545 3/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9097179 0.86 FHIT (0.72) KDM4EFHITALDH1A1MAPTMEN1
SCHEMBL10714467 0.83 KDM4E (0.50) KDM4EFHITCYP1A2ALDH1A1MAPT
Hydrochloric Acid SCHEMBL10731684 0.81 KDM4E (0.49) KDM4EFHITCYP1A2ALDH1A1MAPT
SCHEMBL3452499 0.80 CYP1A2 (0.55) KDM4EFHITCYP1A2ALDH1A1MAPT
SCHEMBL8201854 0.80 FHIT (0.49) KDM4EFHITCYP1A2ALDH1A1MAPT
SCHEMBL3059204 0.80 FHIT (0.67) KDM4EFHITALDH1A1MAPTMEN1
SCHEMBL1063435 0.78 KDM4E (0.60) KDM4EFHITALDH1A1MAPTMEN1
SCHEMBL10713052 0.76 ALDH1A1 (0.62) KDM4EFHITALDH1A1MAPTCNR2
SCHEMBL3059208 0.75 FHIT (0.56) KDM4EFHITALDH1A1MAPTMEN1
SCHEMBL10714409 0.74 GRM6 (0.68) KDM4EALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118047791-A URAT1 inhibitor containing aminopyridine structure, and preparation method and application thereof 山东省药学科学院 2024-05-17 CN disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 US disclosed
EP-0799230-A1 THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS SMITHKLINE BEECHAM PLC (GB) 1997-10-08 EP disclosed
WO-1996019482-A1 THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS SMITHKLINE BEECHAM PLC (GB) 1996-06-27 WO disclosed
US-4692461-A PLANT PROTECTION BAYER AKTIENGESELLSCHAFT (DE) 1987-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 KDM4E 1572/4885FHIT 3933/4885CYP1A2 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.